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Abstract
Background: Opioids are the mainstay of therapy for painful vasoocclusive episodes (VOEs) in sickle cell
disease (SCD). Based on limited studies, low-dose ketamine could be a useful adjuvant analgesic for refractory SCD
pain, but its safety and efficacy has not been evaluated in pediatric SCD.
Procedure: Using retrospective chart review we recorded and compared characteristics of hospitalizations of
33 children with SCD hospitalized with VOE who were treated with low-dose ketamine and opioid PCA vs. a paired
hospitalization where the same patients received opioid PCA without ketamine. We seek to 1) describe a single
center experience using adjuvant low-dose ketamine with opioid PCA for sickle cell related pain, 2) retrospectively
explore the safety and efficacy of adjuvant low-dose ketamine for pain management, and 3) determine ketamine’s
effect on opioid consumption in children and adolescents hospitalized with VOE.
Results: During hospitalizations where patients received ketamine, pain scores and opioid use were higher (6.48
vs. 5.99; p=0.002 and 0.040 mg/kg/h vs. 0.032 mg/kg/h; p=0.004 respectively) compared to hospitalizations without
ketamine. In 3 patients, ketamine was discontinued due to temporary and reversible psychotomimetic effects. There
were no additional short term side effects of ketamine.
Conclusions: Low-dose ketamine has an acceptable short-term safety profile for patients with SCD hospitalized
for VOE. Lack of an opioid sparing effect of ketamine likely represents use of low-dose ketamine for patients
presenting with more severe VOE pain. Prospective randomized studies of adjuvant low-dose ketamine for SCD
pain are warranted to determine efficacy and long-term safety.

Keywords: Sickle cell disease; Red blood cell disorders;
Hemoglobinopathies; Pain; Pain medicine; Anemia’s

Introduction
Painful vaso-occlusive episodes (VOEs) are the hallmark of sickle
cell disease (SCD). These episodes of recurrent pain are caused by tissue
ischemia, resulting from occlusion of the microcirculation by sickled
red blood cells and are the most frequent complication of (SCD) [1].
Frequency and intensity of painful episodes are variable among patients
with SCD. Some patients are rarely hospitalized for pain management,
while others are often admitted for treatment with intravenous (IV)
opioids. These frequently hospitalized patients may have pain that is
refractory to conventional therapies for multifactorial reasons, and this
can lead to sub-optimal pain control and frustration for both patients
and clinicians [2,3].
Traditional inpatient therapy for VOE includes IV hydration
combined with administration of non-steroidal anti-inflammatory
agents (NSAIDS) and IV opioids, often delivered via patientcontrolled analgesia (PCA) pump [4]. Additionally, supportive care
and complementary and alternative therapies have been described
as helpful adjuvants in the management of SCD patients with acute
painful episodes [5-10]. For frequently hospitalized SCD patients with
a recurrent severe pain phenotype, this combination is not always
effective in achieving pain relief. It has been hypothesized that frequent
exposure to opioids in these patients could lead to tolerance and, in
extreme cases, opioid induced hyperalgesia (OIH), which are thought
to contribute to opioid refractory pain [11-13]. Activation of the
N-methyl-D-aspartate (NMDA) receptor has been implicated in opioid
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tolerance and OIH. Ketamine is an inhibiter of the NMDA receptor
and has been shown to modulate opioid tolerance and OIH in both
children and adults with perioperative and cancer-related pain [14-17].
While limited data is available, subanesthetic doses known as low-dose
ketamine can be given as an IV bolus dose of less than 1 mg/kg or a
continuous infusion at a rate of less than 1.2 mg/kg/h. At these doses
ketamine does not appear to possess the sedative properties seen with
higher anesthetic doses [18].
There is limited experience with the use of low-dose ketamine
in SCD. Case series and case reports have documented improved
analgesia, although some clinically significant side effects such as
nystagmus, hypertension, dysphoria, and unresponsiveness were
also noted. While most of these clinically significant side effects were
associated with bolus dosing of ketamine, safety concerns remain
with the use of low-dose ketamine in this population [19,20]. We here
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present our experience with the use of adjuvant low-dose ketamine
in children and adolescents with SCD hospitalized for painful VOE,
and provide preliminary examination of its safety and efficacy in this
population through a retrospective case-crossover study design.

Materials and Methods
Research design and data sources
This study was approved by the Institutional Review Board of
Children’s National Medical Center. Through retrospective chart
review of pharmacy records, we identified patients with SCD who
had received ketamine between September 1, 2010 and May 8, 2012.
We then retrospectively selected and compared two painful VOE
hospitalizations for each patient separated by a maximum of 24
months. In one hospitalization the patient received adjuvant lowdose ketamine infusion in addition to opioid PCA, at the discretion of
the pain medicine physician. In the other hospitalization, the patient
received opioid PCA alone, without adjuvant ketamine. All patients in
both groups received standard care with NSAIDS, IV hydration, and
supportive care interventions.
Patients with SCD, 7-21 years old, with an admitting diagnosis
of VOE, with or without an admission diagnosis of pneumonia or
acute chest syndrome (ACS) were included. All demographics and
hospitalization details, including pain and sedation scores every 4 hours
and daily opioid administration (measured in morphine equivalents),
were recorded through review of the electronic medical record (EMR).
Pain scores that had been recorded using either the Numeric Rating
Scale (NRS) or the Wong-Backer Faces Scale, and sedation scores
that had been assessed utilizing The University of Michigan Sedation
Scale (UMMS) were documented during the chart review [21,22].
Comorbidities such as history of asthma, priapism, kidney disease, or
avascular necrosis, were also recorded from the EMR.

Endpoints
Our primary endpoint to assess efficacy of adjuvant ketamine was
daily opioid consumption during the hospitalizations. We compared
the hospitalizations with and without adjuvant ketamine to determine a
possible opioid-sparing effect of ketamine. To convert total daily opioid
dose to IV morphine equivalents we used the following conversions:
codeine to oral morphine (10:1), oxycodone: oral morphine (1:1.5),
oral morphine: IV morphine (3:1), IV/oral hydromorphone: IV/oral
morphine (5:1), tramadol: oral morphine (5:1), oral methadone: oral
morphine, (1:4), oral methadone : intravenous methadone (2:1) [23,24].
Short term safety was assessed by recording when and if adjuvant lowdose ketamine infusion was discontinued due to a suspected adverse
event as documented in Pain Medicine progress notes. The sedative
effect of adjuvant low-dose ketamine was assessed by noting recorded
sedation scores. Secondary endpoints assessed through chart review
included pain and sedation scores, administration of anti-emetics and
antihistamines, and use of complementary and alternative therapies. Use
of alternative pain management agents was defined as administration of
gabapentin, pregabalin, duloxetine, fluoxetine, diazepam, or lorazepam
and was also assessed through chart review.

Data management and analysis
All study data was managed in REDCap electronic data capture
tools hosted at Children’s National Medical Center [25]. The data
was exported from REDCap to SAS 9.2 (SAS Institute, Cary, NC)
for statistical analysis. We compared demographic and clinical
characteristics of patient hospitalizations when they were treated
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with and without ketamine using univariate frequency distributions.
Exploratory bivariate analyses (McNemar’s test and paired t-test for
significant differences between paired samples) were used to compare
variables between the paired hospitalizations. Multiple linear regressions
was used with the continuous dependent variable of mean opioid use to
attempt to control for key confounders including diagnosis of ACS, red
blood cell transfusion, number of painful sites, pain score, and length
of stay.

Results
Thirty-three paired hospitalizations that occurred between October
2008 and April 2012 met the study eligibility criteria. Demographic
data reflective of the time of presentation for the PCA and ketamine
hospitalization is presented in Table 1. The mean age of our patients
was 15.6 years (range 7.5-21.4 years) and 67% were females. The mean
duration until low-dose ketamine started was 1.17 days, with the
majority of patients having low-dose ketamine added on hospital day
2 or 3. The mean interval time between a patient’s 2 hospitalizations
was 5.4 months (± 4.5 months, range=0.25 -19.3 months). We collected
data on 242 paired inpatient days between the two hospitalizations.
Twenty-six out of 33 patients (79%) had the PCA alone hospitalization
before their PCA and ketamine hospitalization. Average number of
hospitalizations in the 6 months prior to presentation for their PCA and
adjuvant ketamine hospitalization was 2.1, and 21/33 patients (64%)
had ≥ 2 hospitalizations in the 6 months prior. Low-dose ketamine
was administered as a continuous infusion (0.1 mg/kg/h) for a mean
duration of 3.11 days (± 2.29 days, range 0.8–11.91 days). In one patient,
low-dose ketamine was temporarily escalated to a dose of 0.15 mg/kg/h.
Three patients (9%) had their low-dose ketamine infusion
discontinued or dose decreased due to a perception of an adverse effect
Age
Mean (range)

15.6 years (7.5-21.4)

Gender
Female

22 (67%)

Phenotype
SS

23 (70%)

SBeta0 Thalassemia

1 (3%)

SC

8 (24%)

SBeta+Thalassemia

1 (3%)

Co-morbidities
Asthma or hx of severe ACS

23 (70%)

Avascular Necrosis

5 (15%)

Iron overload

3 (9%)

Kidney Disease/HTN

6 (18%)

Priapism

1 (3%)

Hydroxyurea therapy
Yes

12 (42%)

Average dose

22.74 mg/kg/day

Time to Ketamine start (± SD (range)

1.17 days (± 0.99)
(0.09-3.56)

PCA type

Morphine 21 (64%)

Hydromorphone 12 (36%)
Day Ketamine Added

HD 1 (n=6)
HD 2 (n=13)
HD 3 (n=7)
HD 4 (n=6)
HD 5 (n=1)

Total Duration of Ketamine (±SD) 3.11 days (± 2.29)
hx=history ACS=Acute Chest Syndrome, HTN=Hypertension, HD=hospital day
Table 1: Demographic Characteristics of Ketamine+PCA group. n=33 patients.
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Mean opioid use during the opioid PCA/low-dose ketamine
hospitalization and opioid PCA only hospitalization was 0.040 (±
SD 0.011) and 0.032 (± SD 0.012) mg/kg/h morphine equivalents
respectively (p=0.0038). Attempts were made to adjust for confounders
impacting opioid use including, ACS, red blood cell transfusion,
transfer to ICU, number of painful sites, and mean pain score through
multiple linear regressions. There was no change in the mean opioid use
after adjustment; therefore only crude opioid use is reported.

Discussion
We describe our experience with adjuvant low-dose ketamine
therapy in children and adolescents with SCD and compare
Length of stay
(days) (range)
Mean pain score on
DOA
Mean daily pain score
Mean daily sedation
score

PCA+ ketamine

PCA

change

p-value

5.6
(2.5-13.7)

4.4
(1.7-8.8)

1.21

0.042°

7.84 (3.5-10)

7.25 (3-10)

0.57

0.078°

6.48 (0-10)

5.99 (0-10)

0.46

0.002°

0.277 (0-1.8)

0.173 (0-1.6)

0.12

0.078°

Duration of PCA (± SD) 4.37 days (± 2.5) 3.4 days (± 1.5) 22.5 hrs

0.050°

Concurrent ACS n (%)

0.013+

ICU transfer n (%)
RBC transfusion n (%)

14 (42%)

5 (15%)

3 (9%)

1 (3%)

0.317+

12 (36%)

7 (21%)

0.059+

DOA=day of admission, ACS=Acute Chest Syndrome, ICU=intensive care unit
°paired t-test, +McNemars test
Table 2: Comparison of Hospitalization Characteristics n=33.
PCA+ ketamine

PCA

p-value+

146/235 (62%)

133/240 (55%)

0.113

≥ 2=54%

≥ 2=45%

0.060

≥ 3=20%

≥ 3=7%

0.0001

Received Antiemetic

24/240 (10%)

33/241 (14%)

0.228

Received Antihistamine

79/240 (33%)

63/242 (26%)

0.060

Days with pain score ≥ 8
Number of painful sites

McNemars test

+

Table 3: Hospitalization characteristics and severity by patient days (n=242 patient
days).
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Use of Integrative Therapies During Hospitalizations
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on the part of the patient, parent, or physician. The patient whose dose
was increased to 0.15 mg/kg/h experienced vivid dreams, for which
the infusion was decreased back to 0.1 mg/kg/h with resolution of
the adverse effect. One patient had delusions after starting the lowdose ketamine infusion. This effect was believed to be multifactorial
and was managed by discontinuation of both the low-dose ketamine
infusion and the continuous infusion of the opioid PCA, as well as
administration of a red blood cell transfusion for severe anemia. The
patient’s symptoms resolved after these interventions. The third patient
had the low-dose ketamine infusion discontinued after 19.6 hours
due to the patient’s complaint of feeling “dizzy” and the lack of effect
perceived by the patient and family. There were no cardiac toxicities
noted. Mean daily sedation score during the opioid PCA/low-dose
ketamine hospitalization was 0.277 (range 0-1.8) vs. 0.173 (range
0-1.6) in the opioid PCA hospitalization, p=0.078. Disease severity and
hospitalization characteristics for each patient, and then by patient days
are presented in Tables 2 and 3. Mean daily pain sores in the opioid
PCA/low-dose ketamine hospitalization was higher at 6.48 vs. 5.99 in
the opioid PCA alone hospitalization (p=0.002). More patients had
concurrent ACS during the opioid PCA+ ketamine hospitalization
vs. the opioid PCA alone hospitalization (42% vs. 15%, p=0.013). The
use of supportive care and complementary therapies during the two
hospitalizations are described in Figure 1.

ketamine + PCA
PCA alone

Figure 1: Use of integrative therapies during hospitalizations.
alernative agents=administration of gabapentin, pregabalin, duloxetine,
fluoxetine, diazepam, or lorazepam.

characteristics of hospitalizations with and without ketamine use.
Ketamine was safe, in the short term, when given as continuous
infusion of 0.1 mg/kg/h as an adjuvant to opioid PCA in children and
adolescents with SCD hospitalized for VOE. Psychotomimetic effects
were infrequent and were reversible with discontinuation of the infusion.
While sedation scores were statistically different, average sedation score
in both groups ranged from 0-1 (awake to mildly sedate) indicating no
clinically significant differences in sedation between the two groups. As
observed in other studies, although not statistically significant, a trend
is seen with fewer anti-emetics used by patients receiving ketamine
[26,27]. In comparison to prior studies, the lack of major adverse effects
suggests that the delivery method and dose used in this study may have
a more favorable side effect profile than bolus dosing for pediatric SCD
patients. Prior case series describing five patients with SCD receiving
low-dose ketamine reported one patient who experienced nystagmus,
hypertension, and unresponsiveness after transition to a new infusion
which was hypothesized to have caused an inadvertent bolus dose.
Another patient in that same case series complained of dysphoria after
the initial ketamine bolus and asked that drug is discontinued [19]. Due
to our study design we are not able to comment on the long term effect
of ketamine, more specifically neuroapoptosis, which has been recently
raised as major concern and potentially results from the exposure of the
developing brain to ketamine [28-30].
We did not observe an opioid sparing effect of low-dose ketamine
in this group of frequently hospitalized patients. In fact, opioid
requirement was higher during the admission when low-dose ketamine
was prescribed. The reasons for this finding could be multifactorial in
this retrospective study. Higher opioid use in the PCA and low-dose
ketamine group could be due to a more severe painful crisis experienced
by patients during their low-dose ketamine/opioid hospitalization.
This is suggested by higher pain scores and increased number of
painful sites during those hospitalizations. The presence of higher
pain scores and increased opioid use in the low-dose ketamine/opioid
PCA hospitalizations is in concert with our Pain Medicine group’s
practice of adding ketamine for patients with more difficult to manage
painful episodes. Furthermore, higher rates of ACS and need for red
blood cell transfusion may also be indicators of a more severe painful
crisis. Most patients had their adjuvant ketamine hospitalization at an
older age which could also be suggestive of progression to more severe
disease overtime. The increased number of painful sites noted during
low-dose ketamine admissions could also reflect progression towards a
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chronic pain phenotype. The mean age of our patients was older than
previously described cohorts of patients with SCD, which could suggest
that older patients are more likely to exhibit evidence of a chronic pain
phenotype and poor responsiveness to opioids leading physicians to
seek additional therapies such as low-dose ketamine [31-33]. Our study
population experienced much higher utilization of physical therapy
services, whirlpool, and heat packs than previously reported [33].
Additionally, higher usage of neuropathic and other alternative pain
management agents were recorded in a statistically significant number
of patients during their ketamine hospitalization which may indicate
the severe and refractory nature of their pain, which likely led to lowdose ketamine administration. Patients with hemoglobin SC disease,
generally considered to have milder disease, also received ketamine for
pain demonstrating presence of this severe pain phenotype across the
SCD genotypes.
Our study population is also remarkable in that about two thirds of
our patients had at least 3 hospitalizations in 6 months indicating that
our sample represents a group of frequently hospitalized patients with
severe disease. Prior studies have shown wide variability in the frequency
of painful VOEs requiring hospitalization. About 5% of patients average
3-10 hospitalizations per year for painful crisis, accounting for 33% of
episodes treated by physicians [3]. Our study group also likely reflects
the poorly compliant adolescent patients, since only 36% of our study
patients were receiving hydroxyurea at the time of hospital admission,
although given the combination of frequent hospitalizations and high
rates of ACS these patients are likely prime candidates for hydroxyruea
therapy [34].
We conclude that for difficult to control pain in children and
adolescents with SCD hospitalized for VOE, low-dose ketamine
infusion has an acceptable short-term safety profile and may be used an
adjuvant to opioids. We were unable to detect an opioid sparing effect of
ketamine in our population which is likely attributable, at least in part,
to the increased severity and chronicity of pain in the PCA plus lowdose ketamine hospitalizations. We cannot comment on the efficacy
of the regimen due to selection bias introduced by our retrospective
non-randomized case-control design, where adjuvant ketamine was
prescribed at the discretion of the treating physician. Additionally,
with a relatively small sample size we were unable to control for disease
severity, pain scores, opioid use, and SCD-related complications,
and pharmacogenetic variations which further impairs our ability
to comment on the efficacy of adjuvant ketamine. Further studies,
including a large prospective randomized control trial that could
address the above mentioned challenges, are necessary to determine the
safety and efficacy of adjuvant ketamine to opioid PCA for patients with
SCD. Efficacy studies should also include long-term safety assessment.
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